Travoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Travoprost: From Open-Angle Glaucoma/Ocular Hypertension to Visceral Calciphylaxis
One-Sentence Summary
Travoprost is a prostaglandin F2α (FP receptor) analogue used topically for open-angle glaucoma and ocular hypertension (inferred from clinical trial context, as no
original_indicationswere recorded). The TxGNN model's top prediction is Visceral Calciphylaxis, but this candidate currently has 0 clinical trials and 0 publications supporting it — the score reflects graph-embedding similarity only, with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma / ocular hypertension (inferred from trial evidence; not present in taiwan_regulatory.licenses) |
| Predicted New Indication | Visceral Calciphylaxis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Norway Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (original_moa: [Data Gap]). Based on known pharmacology, travoprost is a synthetic prostaglandin F2α analogue and FP receptor agonist; its established clinical use is lowering intraocular pressure via increased uveoscleral outflow in glaucoma/ocular hypertension.
For the top-ranked candidate, visceral calciphylaxis, the evidence pack's own rationale explicitly states there is no direct or indirect clinical evidence, and no known mechanistic link — calciphylaxis pathology centers on vascular calcification and microthrombosis, which is not connected to FP receptor signaling. The high TxGNN score reflects graph-embedding similarity in the knowledge graph, not a validated pharmacological hypothesis.
It is worth noting that among the other nine predicted indications in this pack, only rank 5 ("vascular disease") has any clinical trial/literature attached, and even those are indirect (ocular vasoactivity findings, hyperemia adverse-event studies) rather than treatment evidence for a systemic vascular disease. Rank 10 ("hemangioendothelioma") is supported only by a case report of travoprost-induced uveal effusion — an adverse-event signal, not a therapeutic one. None of the ten predictions in this pack currently meet a credible mechanistic or clinical bar.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Travoprost currently has no marketing authorization on record (market_status: 未上市 / Not marketed; total_licenses: 0). No license entries are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all currently unavailable — see data gaps DG001/DG002 below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (visceral calciphylaxis) has zero clinical trials, zero literature, and an explicitly stated absence of mechanistic plausibility in the evidence pack itself — this is a pure model-similarity signal (L5) with no corroborating evidence of any kind.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking — currently blocks S1 safety screening)
- Verified mechanism of action data from DrugBank (DG002, High priority)
- Preclinical or mechanistic studies linking FP receptor agonism to vascular calcification pathology
- If pursuing rank 5 ("vascular disease") instead, systemic (non-ocular) pharmacokinetic/exposure data, since current evidence is limited to topical ocular effects
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.